Intervacc AB
Research Intervacc AB (IVACC) on Bullrun: market cap SEK 443.06M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIVACC
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 443.06M
- Financial periodQ4 2025
- RevenueSEK 3.12M
- Net income-SEK 35.57M
- Free cash flow-SEK 11.46M
- Gross margin-536.7%
Valuation Snapshot
latest market cap is SEK 443.06M.
About Intervacc AB
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows.
Frequently asked questions
What is Intervacc AB's market cap?
Intervacc AB's market capitalization is SEK 443.06M.
What does Intervacc AB do?
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets;